Neuraxis

Neuraxis Debt

The Debt of Neuraxis (NRXS) as of Nov 22, 2026 is 416,611.00 USD. In the previous year, Debt was 473,405.00 USD — a change of -12.00% (lower).

Debt

416,611.00USD

YoY

-12.00%

Last updated:

In 2025, Neuraxis's total debt was 416,611.00 USD, a -12.00% change from the 473,405.00 USD total debt recorded in the previous year.

The Neuraxis Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2020
311,492.00 USD
Jan 1, 2021
439,275.00 USD
Jan 1, 2022
598,821.00 USD
Jan 1, 2023
224,260.00 USD
Jan 1, 2024
473,405.00 USD
Jan 1, 2025
416,611.00 USD
The Neuraxis Debt history
YEARDebtYoY
416,611.00USD-12.00%
473,405.00USD+111.10%
224,260.00USD-62.55%
598,821.00USD+36.32%
439,275.00USD+41.02%
311,492.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Debt Details

Understanding Neuraxis's Debt Structure

Neuraxis's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Neuraxis's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Neuraxis’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Neuraxis’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Neuraxis stock

Debt of Neuraxis is 416,611.00 USD in 2025.

Debt of Neuraxis changed from 473,405.00 USD to 416,611.00 USD, representing a -12.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Neuraxis since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Neuraxis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuraxis

All Key Metrics — Neuraxis